Preoperative levosimendán and Hip Fracture

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether preoperative optimization with levosimendan in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue perfusion parameters.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario de Canarias
• Collaborator: Orion Corporation, Orion Pharma
• Treatments: Simendan

Criteria

Inclusion Criteria:

1. Patients due to undergo urgent of hip fracture.

2. Patients with cardiac failure (EF < 45 %).

3. Decompensated heart failure.

4. Informed consent provided by the patient.

Exclusion Criteria:

1. <18 years old

2. Emergency surgery

3. Serious aortic stenosis (< 1 cm2)

4. Sustained ventricular tachycardia or atrial fibrillation >140

5. Earlier episodes of "torsades depointes"

6. Systolic blood pressure < 85 mmHg

7. Serious kidney failure (GFR < 30 ml/min)

8. Serious liver failure (known class C Child-Pugh score)

9. Allergy levosimendan